STOCK TITAN

Revance Therapeutics, Inc. - $RVNC STOCK NEWS

Welcome to our dedicated page for Revance Therapeutics news (Ticker: $RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics stock.

Revance Therapeutics, Inc. (symbol: RVNC) is a specialty biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative botulinum toxin products for various aesthetic and therapeutic uses. Leveraging its proprietary portfolio of botulinum toxin compounds and the patented TransMTS® peptide delivery system, Revance aims to address unmet needs in the $3 billion neurotoxin market.

The company’s unique TransMTS technology allows for the delivery of botulinum toxin A in two distinctive formulations: a needle-free topical form and an injectable form that targets the site of injection for a potentially longer-lasting effect. Revance is actively pursuing clinical development for two main product candidates: Topical RT001 and Injectable RT002. RT001 is a topical gel with the potential to become the first commercially available non-injectable botulinum toxin dose form.

Additionally, Revance has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Their primary products, DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics, are central to their aesthetic and therapeutic offerings.

Revance operates through two main business segments: Product and Service. The Products segment, which generates the majority of the company’s revenue, focuses on the research and development of aesthetic and therapeutic products. Recent achievements and ongoing developments reflect the company’s commitment to advancing the field of neuromodulation.

Rhea-AI Summary

Revance Therapeutics (NASDAQ: RVNC) announced its participation in two upcoming investor conferences. CFO Tobin Schilke will present at the William Blair 44th Annual Growth Stock Conference on June 4, 2024, in Chicago. CEO Mark J. Foley will speak at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. Live audio webcasts will be accessible via Revance's Investor Relations webpage, with replays available for 90 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
conferences
-
Rhea-AI Summary

Revance Therapeutics, Inc. (NASDAQ: RVNC) reported total net product revenue of $51.7 million, with a YoY increase of 13%. DAXXIFY® net revenue was $22.1 million, and RHA® Collection net revenue was $29.6 million. Aesthetic units sold increased by 105% YoY despite seasonality. Revance expects total net product revenue for 2024 to be at least $280 million. Cash, cash equivalents, and short-term investments were $277.1 million as of March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.61%
Tags
-
Rhea-AI Summary

Revance Therapeutics, Inc. (NASDAQ: RVNC) has launched DAXXIFY for the treatment of cervical dystonia, a long-lasting neurotoxin. The product has secured coverage for 78% of commercial lives, marking the company's entry into the $2.7 billion U.S. therapeutic neurotoxin market. With FDA approval in August 2023, Revance aims to address the unmet needs of patients, physicians, and payers by providing a differentiated treatment option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.61%
Tags
none
Rhea-AI Summary

Revance Therapeutics, Inc. (NASDAQ: RVNC) will release its first quarter 2024 financial results on May 9, 2024, followed by a conference call and webcast to discuss the results and provide a corporate update. The conference call will be accessible for U.S. callers and other locations, with a webcast replay available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.77%
Tags
-
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) presented two posters at the AAN meeting on DAXXIFY® for cervical dystonia treatment. Data showed customizable retreatment intervals and benefits of DAXXIFY's formulation. The studies suggest long-acting symptom control, low adverse event rates, and potential for tailored treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
conferences
-
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) grants 222,452 RSUs to 29 new employees, with vesting over four years, subject to continued service. The awards were approved by the Compensation Committee as inducements for employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) priced an underwritten public offering of 16 million shares of common stock at $6.25 per share, expecting to raise $100 million in gross proceeds. The offering is set to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.04%
Tags
-
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) announces a proposed underwritten public offering of $100 million of its common stock, with an option for additional shares. The company plans to utilize the proceeds for commercial growth, product launches, and general corporate purposes. Barclays is the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.04%
Tags
-
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) reported strong financial results for Q4 and full year 2023, with product revenue reaching $58.5 million and $212.7 million, respectively. The company achieved significant YoY growth of 28% and 80%. The 2024 revenue guidance stands at $280 million, showcasing blockbuster potential in U.S. aesthetics. DAXXIFY for cervical dystonia is on track for a mid-year launch, with positive financial outlook and a focus on achieving positive Adjusted EBITDA in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.15%
Tags
Rhea-AI Summary
Revance Therapeutics (RVNC) to Release Q4 and Full Year 2023 Financial Results on February 28, 2024, with a Conference Call and Webcast to Discuss Results and Corporate Update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags

FAQ

What does Revance Therapeutics, Inc. specialize in?

Revance Therapeutics, Inc. specializes in developing, manufacturing, and commercializing novel botulinum toxin products for aesthetic and therapeutic uses.

What is the TransMTS® peptide delivery system?

The TransMTS® peptide delivery system is Revance's patented technology for delivering botulinum toxin A in both needle-free topical and injectable forms.

What are the main products of Revance Therapeutics?

The main products are DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA for Injection Aesthetics, the RHA Collection of dermal fillers, and the HintMD platform.

What is RT001?

RT001 is a topical gel in development by Revance, which could become the first commercially available non-injectable botulinum toxin dose form.

What are the business segments of Revance Therapeutics?

Revance operates through Product and Service segments, with the Products segment generating the majority of the revenue.

How does Revance's TransMTS technology benefit its products?

TransMTS technology allows for targeted and potentially longer-lasting delivery of botulinum toxin, addressing unmet needs in the neurotoxin market.

What is the significance of DaxibotulinumtoxinA?

DaxibotulinumtoxinA is a key product for both aesthetic and therapeutic uses, reflecting Revance's innovation in neuromodulation.

What is the RHA Collection?

The RHA Collection is a line of dermal fillers included in Revance's prestige aesthetics portfolio.

What is the HintMD platform?

HintMD is a platform included in Revance's aesthetics portfolio, enhancing their offerings in the aesthetic market.

How does Revance's Product segment contribute to its revenue?

The Product segment focuses on research and development of aesthetic and therapeutic products, generating the majority of Revance's revenue.

Revance Therapeutics, Inc.

Nasdaq:RVNC

RVNC Rankings

RVNC Stock Data

307.08M
70.80M
8.48%
76.13%
13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NASHVILLE

About RVNC

revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form